Phase II Topical Interferon Alpha-2b trial for AGW: Helix BioPharma achieves last-patient-out

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced today that it has achieved last-patient-out in its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW).  Accordingly, all patients enrolled in the study have completed the prescribed study procedures, and Helix will now proceed to closing of the database and analysis of the results.  Based on the trial design and schedule, final reporting is expected in mid to late calendar 2010, as previously announced.

SOURCE Helix BioPharma Corp.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Omicron lineage spike proteins use ACE2 receptors more efficiently